IMM Immutep granted US patent for IMP321 22/03/19 PRICE SENSITIVE Share IMM IMP761 results presented at ECCO conference 08/03/19 PRICE SENSITIVE Share IMM Immutep receives A$872,351 R&D Tax Incentive 07/03/19 PRICE SENSITIVE Share IMM Immutep doses First Patient in TACTI-002 Phase II Trial 06/03/19 PRICE SENSITIVE Share IMM TACTI-mel data presented at World Immunotherapy Congress 06/03/19 PRICE SENSITIVE Share IMM Half Year Accounts 27/02/19 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 24/01/19 PRICE SENSITIVE Share IMM Immutep enters into collaboration with CYTLIMIC 07/01/19 PRICE SENSITIVE Share IMM Cleansing prospectus for issue of warrants 20/12/18 PRICE SENSITIVE Share IMM Immutep announces US$5.2 million capital raising 19/12/18 PRICE SENSITIVE Share IMM European patent granted for IMP321 & antibody combinations 29/11/18 PRICE SENSITIVE Share IMM Immutep granted European patent for IMP321 28/11/18 PRICE SENSITIVE Share IMM Immutep presents new TACTI-mel data at ICI Europe Summit 27/11/18 PRICE SENSITIVE Share IMM Positive interim TACTI-mel data presented at SITC 12/11/18 PRICE SENSITIVE Share IMM Operational Update 01/11/18 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 25/10/18 PRICE SENSITIVE Share IMM Immutep enters into collaboration with Pfizer & Merck KGaA 24/09/18 PRICE SENSITIVE Share IMM Progress towards clinical development of IMP761 03/09/18 PRICE SENSITIVE Share IMM Appendix 4E & 2018 Full Year Statutory Accounts 21/08/18 PRICE SENSITIVE Share IMM Immutep receives A$1.9M from French R&D tax cash rebate 21/08/18 PRICE SENSITIVE Share IMM TACTI-mel Patient Recruitment Complete & Operational Update 07/08/18 PRICE SENSITIVE Share IMM Immutep secures Canadian patent grant for IMP731 antibody 07/08/18 PRICE SENSITIVE Share IMM Immutep receives IND approval from US FDA for IMP321 31/07/18 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 30/07/18 PRICE SENSITIVE Share IMM Immutep submits IND application with FDA 02/07/18 PRICE SENSITIVE download Created with Sketch. 214.46KB Share IMM Mid-point of patient enrolment reached in AIPAC trial 19/06/18 PRICE SENSITIVE download Created with Sketch. 212.37KB Share IMM Webcast slides for TACTI-mel clinical trial data 30/05/18 PRICE SENSITIVE download Created with Sketch. 1.62MB Share IMM New Data from Ongoing TACTI-mel Study 30/05/18 PRICE SENSITIVE download Created with Sketch. 163.67KB Share IMM Response to ASX Price Query 15/05/18 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 23/04/18 PRICE SENSITIVE Share IMM Operational Update 03/04/18 PRICE SENSITIVE Share IMM Immutep raises A$6.85M through institutional placement 12/03/18 PRICE SENSITIVE Share IMM Immutep enters into collaboration with MSD 12/03/18 PRICE SENSITIVE Share IMM US patent grant for IMP701 antibody 06/03/18 PRICE SENSITIVE Share IMM Immutep receives A$686,704 R&D Tax Incentive 05/03/18 PRICE SENSITIVE Share IMM Half Yearly Report and Accounts 22/02/18 PRICE SENSITIVE Share IMM Outcome of DSMB Safety Review & Extension of TACTI-mel 09/02/18 PRICE SENSITIVE Share IMM Immutep receives USD1M milestone payment from EOC 01/02/18 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 22/01/18 PRICE SENSITIVE Share IMM Operational Update 12/12/17 PRICE SENSITIVE Share IMM European patent grant for IMP321 in cancer 22/11/17 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 11/10/17 PRICE SENSITIVE Share IMM Japanese Patent Grant for IMP731 Antibody 08/09/17 PRICE SENSITIVE Share IMM Japanese Patent Grants For IMP321 In Infectious Disease 05/09/17 PRICE SENSITIVE Share IMM PRR & Monash Uni receive funding grant for LAG-3 Research 30/08/17 PRICE SENSITIVE Share IMM Appendix 4E & 2017 Full Year Statutory Accounts 28/08/17 PRICE SENSITIVE Share IMM French government research cash rebate of A$1.3M received 16/08/17 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 18/07/17 PRICE SENSITIVE Share IMM Financial Update 18/07/17 PRICE SENSITIVE Share IMM 2nd milestone payment to be received from Novartis 17/07/17 PRICE SENSITIVE Share IMM Approvals received to initiate INSIGHT clinical trial 10/07/17 PRICE SENSITIVE Share IMM Disclosure Under LR 3.10.5A and 7.1A.4(b) 06/07/17 PRICE SENSITIVE Share IMM Form 6-K 30/06/17 PRICE SENSITIVE Share IMM Form 6-K 30/06/17 PRICE SENSITIVE Share IMM USD 5 Million Capital Raising 30/06/17 PRICE SENSITIVE Share IMM Preliminary Prospectus Supplement 30/06/17 PRICE SENSITIVE Share IMM Operational Update 26/06/17 PRICE SENSITIVE Share IMM IMP321 demonstrates positive safety & efficacy qualities 05/06/17 PRICE SENSITIVE Share IMM Approval received to commence 3rd cohort of melanoma trial 19/04/17 PRICE SENSITIVE Share IMM $492k R&D Tax Incentive Refund Received 12/04/17 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 12/04/17 PRICE SENSITIVE Share IMM PRR completes recruitment for 2nd patient cohort 15/03/17 PRICE SENSITIVE Share IMM S&P DJ Indices Announces March Quarterly Rebalance 10/03/17 PRICE SENSITIVE Share IMM US patent granted for IMP321 01/03/17 PRICE SENSITIVE Share IMM Half Yearly Report and Accounts 24/02/17 PRICE SENSITIVE Share IMM Operational Update 24/02/17 PRICE SENSITIVE Share IMM French Research Tax Credit Payment Received 13/02/17 PRICE SENSITIVE Share IMM PRR commences randomised phase IIb clinical trial 20/01/17 PRICE SENSITIVE Share IMM Prima commences recruitment for 2nd cohort of melanoma trial 12/01/17 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 06/01/17 PRICE SENSITIVE Share IMM Prima Enters New MTA with CYTLIMIC 05/01/17 PRICE SENSITIVE Share IMM Prima announces new LAG-3 agonist antibody product candidate 03/01/17 PRICE SENSITIVE Share IMM Prima announces TACTI-mel clinical trial data 29/12/16 PRICE SENSITIVE Share IMM Prima announces AIPAC clinical trial data 22/12/16 PRICE SENSITIVE Share IMM Prima receives UK approval for AIPAC study 20/12/16 PRICE SENSITIVE Share IMM Wuxi & Prima sign MOU for strategic partnership 23/11/16 PRICE SENSITIVE Share IMM Appendix 4C - quarterly-PRR.AX 19/10/16 PRICE SENSITIVE Share IMM Appendix 4E & 2016 Full Year Statutory Accounts-PRR.AX 31/08/16 PRICE SENSITIVE Share IMM European Patent Grants for IMP731 Antibody-PRR.AX 28/08/16 PRICE SENSITIVE Share IMM European Patent Grants for IMP731 Antibody-PRR.AX 25/08/16 PRICE SENSITIVE Share IMM Operational Update-PRR.AX 18/08/16 PRICE SENSITIVE Share IMM Appendix 4C - quarterly-PRR.AX 27/07/16 PRICE SENSITIVE Share IMM PRR Collaborates In New Clinical Trial For Imp321-PRR.AX 12/07/16 PRICE SENSITIVE Share IMM First Data From Phase IIb Clinical Trial of Imp321-PRR.AX 22/06/16 PRICE SENSITIVE Share IMM Prima BioMed Files U.S Shelf Registration Statement-PRR.AX 30/05/16 PRICE SENSITIVE Share IMM PRR Enters Agreement with Sydys to Advance CVac Program-PRR.AX 12/05/16 PRICE SENSITIVE Share IMM Japanese Patent Grants For IMP321 In Cancer-PRR.AX 02/05/16 PRICE SENSITIVE Share IMM Response to ASX Price Query-PRR.AX 21/04/16 PRICE SENSITIVE Share IMM Appendix 4C - quarterly March 2016-PRR.AX 08/04/16 PRICE SENSITIVE Share IMM First patient dosed in AIPAC 02/03/16 PRICE SENSITIVE Share IMM Half Yearly Report and Accounts 29/02/16 PRICE SENSITIVE Share IMM US patent granted for IMP731 antibody 28/01/16 PRICE SENSITIVE Share IMM Prima initiates Phase I melanoma study in Australia 27/01/16 PRICE SENSITIVE Share IMM Response to ASX Price Query 08/01/16 PRICE SENSITIVE Share IMM Appendix 4C - quarterly 07/01/16 PRICE SENSITIVE Share IMM Prima initiates phase IIb study in metastatic breast cancer 22/12/15 PRICE SENSITIVE Share IMM Prima Progresses Japanese Collaboration 11/12/15 PRICE SENSITIVE Share IMM $420k R&D Tax Incentive Refund Received 26/11/15 PRICE SENSITIVE Share IMM Prima unveils Phase I combination study of IMP321 18/11/15 PRICE SENSITIVE Share IMM Prima announces A$2m investment from institutional investor 30/10/15 PRICE SENSITIVE Share
(20min delay)
